Reply
We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States.1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et  al2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 10, 2024 Category: Gastroenterology Authors: Markos Kalligeros, Eleftherios Mylonakis, Mazen Noureddin Tags: Letters to the Editor Source Type: research

Steatotic Liver Disease: Advancing Science and Patient Care Beyond Traditions
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 10, 2024 Category: Gastroenterology Authors: Markos Kalligeros, Eleftherios Mylonakis, Mazen Noureddin Tags: Letter to the Editor Source Type: research

Dissecting Geographical and Racial Disparities in H. pylori Infection Rates: Screening and Eradication Strategies in the U.S.
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 10, 2024 Category: Gastroenterology Authors: Yasutoshi Shiratori, Naoki Ishii, Anthony Kalloo Tags: Letter to the Editor Source Type: research

Glucagon-Like Peptide-1 Receptor Agonists in Patients With Cirrhosis: Answering the Unanswered Questions?
Nonalcoholic fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD),1 continues to be a growing public health issue, with cirrhosis-related mortality increasing at an alarming pace.2 Many studies have researched the use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with MASLD/metabolic dysfunction-associated steatohepatitis with demonstrable effects on reducing liver fat and lowering cardiovascular events.3 In a recent phase 2 trial in patients with metabolic dysfunction-associated steatohepatitis compensated cirrhosis, semaglutide did not significantly improve...
Source: Clinical Gastroenterology and Hepatology - February 9, 2024 Category: Gastroenterology Authors: Sara Mahgoub, Philip N. Newsome Tags: Editorial Source Type: research

From ChatGPT to GutGPT: Enhancing AI for Personalized Health Care
We recently read with great interest the recent study by Kerbage et  al,1 which accessed the accuracy of Chat Generative Pre-trained Transformer (ChatGPT) in addressing queries related to prevalent gastrointestinal diseases. The study revealed that ChatGPT demonstrated an 84% accuracy rate in responding to issues concerning inflammatory bowel disease, irritable bow el syndrome, colonoscopy, and colorectal cancer screening. This outcome bolsters the potential of ChatGPT as a physician educational tool, particularly in the realm of gut health care. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 9, 2024 Category: Gastroenterology Authors: Qingzhou Kong, Yueyue Li, Yanqing Li Tags: Letters to the Editor Source Type: research

From ChatGPT to GutGPT: Enhancing AI for Personalized Healthcare
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 9, 2024 Category: Gastroenterology Authors: Qingzhou Kong, Yueyue Li, Yanqing Li Tags: Letter to the Editor Source Type: research

Glucagon-like peptide-1 receptor agonists in patients with cirrhosis – answering the unanswered questions?
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 9, 2024 Category: Gastroenterology Authors: Sara Mahgoub, Philip N. Newsome Tags: Editorial Source Type: research

Feasibility and Colonoscopy Yield Using the Fecal Immunochemical Test (FIT)-Based Colorectal Cancer Screening in a Latin America Country
Organized colorectal cancer (CRC) screening is not widely practiced in Latin America and the results of regional studies may help overcome barriers for implementation of national screening programs. We aimed to describe the implementation and findings of a fecal immunochemical test (FIT)-based program in Brazil. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 8, 2024 Category: Gastroenterology Authors: Mauricio Paulin Sorbello, Ulysses Ribeiro J únior, José Eluf-Neto, Vinicius Pfuetzenreiter, Afonso Henrique da Silva e Sousa Junior, Fábio Shiguehissa Kawaguti, Diane Dede Cohen, Evandro Sobroza de Mello, Sergio Carlos Nahas, Adriana Vaz Safatle-Ribeir Source Type: research

Feasibility and Colonoscopy Yield using the Fecal Immunochemical Test (FIT)-based Colorectal Screening in a Latin America Country
Organized colorectal cancer (CRC) is not widely practiced in Latin America and the results of regional studies may help overcome barriers for implementation of national screening programs. We aimed to describe the implementation and findings of a fecal immunochemical test (FIT)-based program in Brazil. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 8, 2024 Category: Gastroenterology Authors: Mauricio Paulin Sorbello, Ulysses Ribeiro J únior, José Eluf-Neto, Vinicius Pfuetzenreiter, Afonso da Silva e Sousa, Fábio Shiguehissa Kawaguti, Diane Dede Cohen, Evandro Sobroza de Mello, Sergio Carlos Nahas, Adriana Vaz Safatle-Ribeiro Source Type: research

Gastric Malignancies in United States in the Period From 2000 to 2018
I read with great interest the article by Rustgi et  al1 and the Editorial by Tan and Morgan2 on the epidemiology of gastric malignancies in the United States. The incidence of noncardia gastric adenocarcinomas showed a steady decrease whereas neuroendocrine tumors (NETs) consistently increased.1 However, there was an overall increase in noncardia g astric cancers in young women.1 Tan and Morgan2 suggested that this increase could be a result of the increase in NETs, postulated to be owing to the increased prevalence of autoimmune gastritis. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 5, 2024 Category: Gastroenterology Authors: Helge L. Waldum Tags: Letters to the Editor Source Type: research

Pathogenic Variant Intraductal Papillary Mucinous Neoplasms Tumors Show Increased Tumor Growth Compared With Those With Familial Pancreatic Cancer Kindreds: Prognostic Indicators
We read with much interest the recent extensive study by Overbeek et  al1 of the Dutch Familial Pancreatic Cancer Surveillance Study working group in which they define the incidence, growth rate, and risk of pancreatic malignancy in patients with pathogenic variants compared with pancreatic cancer kindreds. They pointed out that a limitation of their study was the l ack of determining IPMN histology, which they ascribed to “common clinical practice.” We agree with this study limitation but note that this limitation may have missed an opportunity to establish accurate histologic diagnosis and better tumor prognosticati...
Source: Clinical Gastroenterology and Hepatology - February 5, 2024 Category: Gastroenterology Authors: Mitchell S. Cappell, Martin Tobi Tags: Letters to the Editor Source Type: research

Low Colorectal Cancer Risk after Resection of High-Risk Pedunculated Polyps
Post-Faecal Immunochemical Test (FIT) colonoscopy represents a setting with an enriched prevalence of advanced adenomas. Due to an expected higher risk of Colorectal Cancer (CRC), post-polypectomy surveillance is recommended, generating a substantially increased load on endoscopy services. The aim of our study was to investigate post-polypectomy CRC risk in a screening population of FIT+ subjects after resection of low- (LRA) or high-risk adenomas (HRA). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 5, 2024 Category: Gastroenterology Authors: Manuel Zorzi, Jessica Battagello, Claudio Barbiellini Amidei, Giulio Antonelli, Bastianello German à, Flavio Valiante, Stefano Benvenuti, Alberto Tringali, Francesco Bortoluzzi, Erica Cervellin, Davide Giacomin, Tamara Meggiato, Erik Rosa Rizzotto, Diego Source Type: research

Gastric malignancies in US in the period 2000-2018
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 5, 2024 Category: Gastroenterology Authors: Helge L. Waldum Tags: Letter to the Editor Source Type: research

Pathogenic variant IPMN tumors show increased tumor growth compared to those with familial pancreatic cancer kindreds: prognostic indicators.
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 5, 2024 Category: Gastroenterology Authors: Mitchell S. Cappell, Martin Tobi Tags: Letter to the Editor Source Type: research

Reply
We express our gratitude to Xu et  al for providing insightful perspectives on the intricate interplay among steatotic liver disease (SLD), systemic metabolic dysfunctions, and chronic hepatitis B (CHB). We agree with Xu et al about the positive association between the burden of metabolic dysfunctions and the severity of hepatic s teatosis in patients with CHB. However, although we found that cumulative metabolic dysfunctions additively increased the hepatitis B surface antigen seroclearance rate among SLD patients,1 probably mediated by the severity of steatosis, we also found that systemic metabolic dysfunctions, espec...
Source: Clinical Gastroenterology and Hepatology - February 4, 2024 Category: Gastroenterology Authors: Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao Tags: Letters to the Editor Source Type: research